Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class ASSE: 603707

Announcement on Obtaining FDA Approval by Subsidiary for Hydralazine Hydrochloride Injection

· Issued by Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Obtaining FDA Approval by Subsidiary for Hydralazine Hydrochloride Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment